TABLE 1

Baseline demographics for subjects in the SAD and MAD phases

ParameterSingle-ascending-dose phaseMultiple-ascending-dose phase
Total TBPM-PI-HBr
(n = 75)
Placebo
(n = 25)
Orapenem
(n = 8)
Total TBPM-PI-HBr
(n = 12)
Placebo
(n = 4)
Age, yrsa26.9 ± 6.727.0 ± 8.725.6 ± 2.424.8 ± 4.528.5 ± 4.7
Male, no. (%)75 (100)25 (100)8 (100)12 (100)4 (100)
Race, no. (%)
    White56 (75)18 (72)7 (88)8 (67)3 (75)
    Asian15 (20)7 (28)1 (13)4 (33)0
    Black or African American01 (25)
    Other4 (5)00
Wt (kg)a75.4 ± 10.179.6 ± 8.971.6 ± 5.574.4 ± 7.074.1 ± 4.0
Ht (cm)a177.7 ± 6.9178.5 ± 5.9176.9 ± 8.0177.2 ± 6.7176.6 ± 3.3
Body mass index (kg/m2)a23.9 ± 3.125.0 ± 2.722.9 ± 1.523.7 ± 2.123.8 ± 1.9
  • a Mean ± SD.